Biome Australia reports first net profit, expands distribution network

Biome Australia announced its first net profit on Sunday, reporting $96,228 (excluding R&D rebate) for the first half of FY25, alongside record half-year sales revenue of $8.86 million.

The microbiome health company reported positive EBITDA of $351,765 for H1 FY25, with Q2 showing an 89 per cent increase to $229,917 compared to Q1. Including R&D rebates, the net profit reached $433,395.

The company expanded its Australian distribution footprint by 20 per cent to 6,000 points during the half, supporting its Vision 27 strategic plan which targets cumulative revenue of $75-85 million between FY25-27.

During the period, Biome launched its cholesterol-lowering probiotic, Biome Cholesterol, which has been ranged by key pharmacy partners. Clinical trials showed the product reduced total cholesterol by 14 per cent and LDL cholesterol by 15 per cent, while increasing HDL cholesterol by 7 per cent compared to baseline.

The company also established operations in Canada through a partnership with Ecotrend Ecologics in September 2024, marking its entry into the North American market.

“The first half of the financial year 2025 has been a remarkable six months for Biome. The milestones, momentum, and scale throughout this period have set the business up well for ongoing success,” said Blair Vega Norfolk, Biome Australia’s Managing Director and Founder.

The company maintained a gross margin of 61 per cent for the six months to 31 December 2024, up from 60 per cent in the previous corresponding period.

Picture: credit Biome